DEA pseudoephedrine proposal lacks "sufficient evidence" of OTC diversion -- NDMA.
This article was originally published in The Tan Sheet
Executive Summary
DEA PSEUDOEPHEDRINE PROPOSAL LACKS "SUFFICIENT EVIDENCE" OF OTC DIVERSION to warrant new reporting requirements, the Nonprescription Drug Manufacturers Association asserted in Jan. 2 comments to the Drug Enforcement Agency. NDMA maintained that the agency's Oct. 31 proposal, which would require retailers to report all single sales of over 24 grams pseudoephedrine base, is "legally insufficient because it does not provide sufficient evidence of OTC pseudoephedrine diversion."